10x Genomics (TXG) Dropped, So What Is Driving Attention Now?

Simply Wall St · 1d ago

AI partnership reshapes 10x Genomics oncology workflow

Lunit is integrating its AI pathology platform, Lunit SCOPE IO, into 10x Genomics (TXG) oncology biomarker discovery studies, pairing whole-slide H&E image analysis with spatial molecular data from the Xenium and Atera systems.

For context, 10x Genomics shares trade at US$75.62 after a one day decline of 6.29%. The stock still carries a 30 day share price return of 16.84% and a 90 day gain of 105.77%, while the 1 year total shareholder return is very large at more than 6x. This points to strong momentum even as short term swings remain sharp around announcements like this AI pathology partnership.

Spot 38 healthcare AI stocks that, like 10x Genomics, are leaning on machine learning to reshape oncology workflows and could be building powerful momentum behind the scenes.

After a 6x one year total return and a share price that now sits well above average analyst targets, 10x Genomics forces a harder question: Is the valuation rich, or is the caution misplaced in light of the AI oncology push?

Most Popular Narrative: 53% Overvalued

On Simply Wall St's most followed storyline, 10x Genomics carries a fair value of $49.54 against the latest close of $75.62. This puts the share price well ahead of that modeled outcome and raises the bar for the AI oncology partnership to justify the gap.

Global investment in genomics, including collaborations like the TISHUMAP initiative and large-scale AI-driven studies using 10x platforms, is increasing the customer base and creating new high-throughput, high-complexity data requirements which 10x is well positioned to supply, driving expanded total addressable market and future revenue upside.

See why 28 investors see 10x Genomics as 53% overvalued.

Result: Fair Value of $49.54 (OVERVALUED)

Still, 10x Genomics faces clear pressure if lower instrument pricing and ongoing operating losses persist, which could test confidence in the AI-driven oncology story.

Find out about the key risks to this 10x Genomics narrative.

Next Steps

Mixed messages run through the 10x Genomics story right now, with enthusiasm around AI in oncology colliding with concerns about valuation and execution. If you want to move past the headline take, weigh both sides of the ledger and study the 1 key reward and 2 important warning signs.

Looking for more 10x Genomics style opportunities?

If 10x Genomics has you rethinking what is possible in your portfolio, broaden your watchlist with ideas that line up with your risk and return goals.

Target quality at a discount by scanning the 30 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their underlying strength.
Build staying power into your portfolio by reviewing the list of solid balance sheet and fundamentals (23 results) that can better handle stress while still offering room for upside.
Hunt for tomorrow's leaders before they hit the headlines by checking out the 16 high quality undiscovered gems hiding strong metrics behind relatively low attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com